RushNet (RushNet) Cash-to-Debt : 0.00 (As of . 20)

View and export this data going back to . Start your Free Trial

What is RushNet Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. RushNet's cash to debt ratio for the quarter that ended in . 20 was 0.00.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, RushNet couldn't pay off its debt using the cash in hand for the quarter that ended in . 20.

The historical rank and industry rank for RushNet's Cash-to-Debt or its related term are showing as below:

RSHN's Cash-to-Debt is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 1.335
* Ranked among companies with meaningful Cash-to-Debt only.

RushNet Cash-to-Debt Historical Data

The historical data trend for RushNet's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

RushNet Cash-to-Debt Chart

RushNet Annual Data

Trend

Cash-to-Debt

RushNet Quarterly Data

Cash-to-Debt

Competitive Comparison of RushNet's Cash-to-Debt

For the Diagnostics & Research subindustry, RushNet's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RushNet's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, RushNet's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where RushNet's Cash-to-Debt falls into.

RushNet Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

RushNet's Cash to Debt Ratio for the fiscal year that ended in . 20 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

RushNet's Cash to Debt Ratio for the quarter that ended in . 20 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

RushNet (OTCPK:RSHN) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

RushNet Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of RushNet's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

RushNet (RushNet) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » RushNet Inc (OTCPK:RSHN) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

8465 Merchants Way, Suite 206, Orange Park, FL, USA, 32222

Website

https://www.rushnetinc.com

RushNet Inc through its subsidiary heliosDX, a National Clinical Reference Laboratory offers High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. The firm provides physicians individualized customer service, as well as fast and accurate reporting of results. The company invests in its infrastructure with the most efficient scientific proven instruments, and latest software for patient and physician satisfaction. It allows heliosDX to provide physicians fast and accurate reporting meeting. The firm excels in patient and client care through physician designed panels that aid in testing compliance and reporting education.